Efficacy and safety of twice-daily olopatadine–mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis

Abstract

GSP301 is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). This meta-analysis aims to evaluate the efficacy and safety of GSP301 in the treatment of allergic rhinitis. A systematic review and meta-analysis were conducted. The data were collected from PubMed, Cochrane Central Register of Controlled Trials and Embase databases till June 2021. In patients with AR, short-term (2/6 weeks) and long-term (52 weeks) effects of GSP301 were assessed. Average morning and evening 12-h reflective total nasal symptom score (rTNSS), instantaneous total nasal symptom score (iTNSS), reflective total ocular symptom score (rTOSS), instantaneous total ocular symptom score(iTOSS), Physician-assessed nasal symptom score (PNSS), rhinoconjunctivitis quality of life (RQLQ), rhinitis control assessment test (RCAT) and adverse events (AEs) were measured. Five randomized controlled trials were included. GSP301 showed greatly improvement in rTNSS (MD\u2009=\u2009– 0.99; [95% CI – 1.19 to – 0.79]; P\u2009<\u20090.01; I2\u2009=\u20090), iTNSS (MD\u2009=\u2009– 1.05; [95% CI – 1.44 to – 0.67]; P\u2009<\u20090.01; I2\u2009>\u200950%), rTOSS (MD\u2009=\u2009– 0.50; [95% CI – 0.72 to – 0.29]; P\u2009<\u20090.01; I2\u2009=\u20090), iTOSS (MD\u2009=\u2009– 0.64; [95% CI – 1.02 to – 0.26]; P\u2009<\u20090.01; I2\u2009>\u200950%), PNSS (MD\u2009=\u2009– 1.01; [95% CI – 1.32 to – 0.69]; P\u2009<\u20090.01; I2\u2009=\u200922.13%), RQLQ (MD\u2009=\u2009– 0.43; [95% CI – 0.57 to – 0.30]; P\u2009<\u20090.01; I2\u2009=\u20090%) and RCAT (MD\u2009=\u20091.94; [95% CI 1.43–2.45]; P\u2009<\u20090.01; I2\u2009=\u20090%) in the short term. No statistical difference was observed in the outcome of long-term PNSS, RQLQ and RCAT. GSP301 is a safe and well-tolerated medication. It showed short-term benefits for seasonal and perennial AR, but may not help to improve patients’ quality of life and rhinitis control in the long run.